FDA Rejects Merck's Proposed Successor to Vioxx
Friday, April 27, 2007 NEW YORK — Merck & Co. (MRK) said Friday that U.S. regulators have rejected its experimental arthritis drug Arcoxia, the drugmaker's follow-up to Vioxx, saying it could not be approved without new supportive data. Wall Street had expected the negative decision by the U.S. Food... Sign in to see full entry.